Who are Anti-diabetic medications's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral Anti Diabetics (OAD), Oral anti-diabetic drugs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-diabetic-medications.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anti-diabetic medications — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-diabetic medications (Anti-diabetic medications) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-diabetic agents (multiple classes). Area: Diabetes.

marketed Anti-diabetic agents (multiple classes) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Anti-diabetic medications (Anti-diabetic medications) — Aristotle University Of Thessaloniki. Anti-diabetic medications work through various mechanisms to lower blood glucose levels by enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Anti-diabetic medications TARGET	Anti-diabetic medications	Aristotle University Of Thessaloniki	marketed	Anti-diabetic agents (multiple classes)
Oral Anti Diabetics (OAD)	Oral Anti Diabetics (OAD)	Sanofi	marketed	Oral Anti-Diabetic Agents (multiple classes)
Oral anti-diabetic drugs	Oral anti-diabetic drugs	Sanofi	phase 3	Oral anti-diabetic agents (multiple classes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-diabetic agents (multiple classes) class)

Aristotle University Of Thessaloniki · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-diabetic medications — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-diabetic-medications. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab